Novacept Sellers Benefited By Running IPO, M&A Processes Simultaneously
This article was originally published in The Gray Sheet
Executive Summary
Novacept cultivated interest among potential acquirers and added value to its eventual $325 mil. selling price by pursuing an IPO while at the same time moving down the merger & acquisition path, according to Piper Jaffray's Jeff Hoffman
You may also be interested in...
Cytyc Expands Women’s Health Niche With Novacept Menorrhagia Treatment
Cytyc will double its sales force targeting ob/gyn physicians to 200 reps following its acquisition of Novacept, in an effort to make NovaSure the top-selling menorrhagia treatment system
IPO Flurry In 2004? Aspirants Stress Profitability, Economic Upturn As Key
Increased access to group purchasing contracts - and a subsequent surge in market share - may provide pulse oximeter developer Masimo with the fiscal confidence to pursue an initial public offering during the second half of the year
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.